Annexon (ANNX) to Release Earnings on Monday

Annexon (NASDAQ:ANNX) is anticipated to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Annexon to post earnings of ($0.32) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Annexon Price Performance

Annexon stock opened at $4.90 on Monday. The stock has a market cap of $586.19 million, a PE ratio of -3.48 and a beta of 1.17. The stock’s fifty day moving average is $5.58 and its two-hundred day moving average is $3.96. Annexon has a 1-year low of $1.28 and a 1-year high of $7.18.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ANNX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, January 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Wells Fargo & Company increased their target price on shares of Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Finally, Chardan Capital started coverage on shares of Annexon in a research note on Tuesday, December 23rd. They set a “buy” rating and a $16.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Key Stories Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

Insider Activity at Annexon

In other news, EVP Dean Richard Artis sold 5,290 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $5.10, for a total transaction of $26,979.00. Following the completion of the sale, the executive vice president owned 123,487 shares in the company, valued at $629,783.70. This represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Overdorf sold 6,225 shares of Annexon stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $31,747.50. Following the completion of the transaction, the executive vice president owned 124,464 shares in the company, valued at approximately $634,766.40. This trade represents a 4.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders acquired 41,230 shares of company stock worth $177,321 and sold 32,513 shares worth $165,973. Insiders own 12.67% of the company’s stock.

Institutional Trading of Annexon

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Landscape Capital Management L.L.C. purchased a new position in Annexon during the fourth quarter worth about $50,000. CIBC Bancorp USA Inc. acquired a new position in Annexon during the 3rd quarter worth approximately $31,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Annexon during the 4th quarter worth approximately $52,000. Engineers Gate Manager LP acquired a new stake in shares of Annexon in the 2nd quarter valued at approximately $32,000. Finally, Cerity Partners LLC purchased a new stake in shares of Annexon in the fourth quarter valued at approximately $74,000.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.